glp 1 atrial fibrillation Multiple GLP-1 drugs linked to lower AFib risk Inflammation may help explain how

GPs are at the front line of managing type 2 diabetes and play a crucial role in regularly assessing and modifying medications in patients with this progressive disease

These drugs have been on the market for a long time but it wasnt until recently with the addition of obesity to their uses that weve seen this uptick in pregnancy cases so the info isnt great

A protective mechanism against protein N-homocysteinylation

It means we do not have enough human data to confirm safety with the same confidence as injectable semaglutide

It is also called NNC 26-0161

[6] Similarly, observational studies using healthcare databases have suggested that patients prescribed GLP-1 agonists for diabetes or obesity appear to have lower rates of alcohol-related hospital admissions and reduced self-reported drinking compared to those on other medications, though these findings are limited by potential confounding factors